Trial reportAfrican health sciences2024
Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study.
Trial report in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editor's choice: Infections, sexual reproductive health and non-communicable diseases.African health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The present comparative study aimed to investigate the effects of different doses of febuxostat on uric acid, inflammatory factors of serum, knee articular cavity, endothelin-1, and oxidative stress in patients with gout. Methods: 80 cases with hyperuricemia admitted to our hospital (January 2018- March 2020) were randomly distributed into two groups. The control group was administered 40 mg of febuxostat tablets daily., whereas the treatment group was administered febuxostat tablets 80 mg daily. Data were collected from two groups of patients, including uric acid level, TNF-α levels of serum and knee articular cavity, vascular endothelial function, and complications 1 month after the intervention. Results: After data intervention, the levels of uric acid, TNF-α levels of serum, and knee articular cavity, NO, and SOD were significantly different between the treatment group and the control group (each p< 0.05). There were no significant differences in abdominal pain and diarrhea, liver damage, kidney damage, acute gout, and pruritus between the two groups (p >0.05). The duration of activity disorder, pain duration, and swelling in the treatment group were significantly shorter than those in the control group (p< 0.05). The uric acid level was positively correlated with serum TNF-α level (p < 0.05), and negatively correlated with NO and SOD levels (p < 0.05). Conclusion: For hyperuricemia-induced gout patients, taking a large dose of 80 mg febuxostat daily can significantly reduce the uric acid level and inflammatory response, improve vascular endothelial function, enhance antioxidant ability, and improve the clinical symptoms of patients without increasing the adverse reactions to medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.